We have recently published two posts regarding the update made to the codes of PhRMA (Pharmaceutical Research and Manufacturers of America) and the IMC (Innovative Medicines Canada).
Now the time has come to talk about Interfarma (Brazilian Association of the Pharmaceutical Research Industry), which has just updated its Code of Conduct, the first edition of which was launched in 2007, with the main purpose of establishing principles of self-regulation, especially in regard to interactions with health professionals. Note that the document was approved in 2012 by the Brazilian Council of Medicine (CFM), by the Brazilian Medical Association (AMB), and by the Brazilian Society of Cardiology.
In 2016, the document underwent its first major review and update, including new sections and regulating the Ethics Council to settle disputes arising from possible reports of Code of Conduct violations.
However, a new review and update introduced some significant changes to the Code of Conduct, as summarized below:
It is worth highlighting that the update was very well done, greatly improving the content of the Code of Conduct and mitigating conflicts of interest and risks associated with the interaction of the pharmaceutical industry with health professionals, patients, patient associations, and public agents.
Some aspects, however, may deserve more attention in upcoming reviews to the Code of Conduct, such as the Rare Disease Market, Donations and Subsidization, Transparency (disclosure of transfer of values from the pharmaceutical industry to health professionals), and Due Diligence and Interaction with Third Parties.
This new Code of Conduct is undoubtedly a remarkable instrument of self-regulation that greatly improves the moral standards of such a complex market.